Jianpi Yangwei decoction promotes apoptosis and suppresses proliferation of 5-fluorouracil resistant gastric cancer cells in vitro and in vivo.


Journal

BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232

Informations de publication

Date de publication:
10 Nov 2020
Historique:
received: 20 02 2020
accepted: 29 10 2020
entrez: 10 11 2020
pubmed: 11 11 2020
medline: 10 7 2021
Statut: epublish

Résumé

The exploration of new therapeutic agents targeting 5-Fu resistance may open a new opportunity to gastric cancer treatment. The objective is to establish a 5-Fu resistant gastric cancer cell line and observe the effect of Jianpi Yangwei decoction (JPYW) on its apoptosis and drug-resistance related proteins. MTT assay was used to measure the effect of JPYW on the BGC823 cells proliferation, and the apoptosis was observed by flow cytometry and Hoechst fluorescence staining. The BGC823 xenograft tumor nude mice models were established, the apoptosis was detected by Tunel method. BGC-823/5-Fu was established by repeated low-dose 5-Fu shocks, the drug resistance index and proliferation were detected by the MTT assay; MDR1 mRNA was detected by real-time RT-PCR; Western blot was used to detect the ratio of p-AKT to AKT; The BGC823/5-Fu xenograft tumor nude mice models were established and apoptosis was measured. The expressions of MRP1, MDR1, ABCG2, AKT, p-AKT, caspase-3 and bcl-2 were detected by immunohistochemistry and the AKT mRNA expression was detected by real-time RT-PCR. JPYW induced apoptosis in BGC823 cells; Drug-resistant cell line BGC-823/5-Fu was sucessfully established; JPYW induced apoptosis of BGC823/5-Fu cells, down-regulated the expression of MRP1, MDR1 and ABCG2 in vitro and in vivo, and further decreased MDR1 expression when combined with pathway inhibitor LY294002 (P < 0.05); JPYW down-regulated the ratio of p-AKT to AKT in vitro in a dose-dependent manner, the same as after the combination with LY294002 (P < 0.05). JPYW can induce apoptosis of BGC823 and BGC823/5-Fu cells, and down-regulate the expression of MDR1, MRP1, ABCG2 in vitro and in vivo. Its in vitro effect is related to the PI3K/AKT signaling pathway.

Sections du résumé

BACKGROUND BACKGROUND
The exploration of new therapeutic agents targeting 5-Fu resistance may open a new opportunity to gastric cancer treatment. The objective is to establish a 5-Fu resistant gastric cancer cell line and observe the effect of Jianpi Yangwei decoction (JPYW) on its apoptosis and drug-resistance related proteins.
METHODS METHODS
MTT assay was used to measure the effect of JPYW on the BGC823 cells proliferation, and the apoptosis was observed by flow cytometry and Hoechst fluorescence staining. The BGC823 xenograft tumor nude mice models were established, the apoptosis was detected by Tunel method. BGC-823/5-Fu was established by repeated low-dose 5-Fu shocks, the drug resistance index and proliferation were detected by the MTT assay; MDR1 mRNA was detected by real-time RT-PCR; Western blot was used to detect the ratio of p-AKT to AKT; The BGC823/5-Fu xenograft tumor nude mice models were established and apoptosis was measured. The expressions of MRP1, MDR1, ABCG2, AKT, p-AKT, caspase-3 and bcl-2 were detected by immunohistochemistry and the AKT mRNA expression was detected by real-time RT-PCR.
RESULTS RESULTS
JPYW induced apoptosis in BGC823 cells; Drug-resistant cell line BGC-823/5-Fu was sucessfully established; JPYW induced apoptosis of BGC823/5-Fu cells, down-regulated the expression of MRP1, MDR1 and ABCG2 in vitro and in vivo, and further decreased MDR1 expression when combined with pathway inhibitor LY294002 (P < 0.05); JPYW down-regulated the ratio of p-AKT to AKT in vitro in a dose-dependent manner, the same as after the combination with LY294002 (P < 0.05).
CONCLUSION CONCLUSIONS
JPYW can induce apoptosis of BGC823 and BGC823/5-Fu cells, and down-regulate the expression of MDR1, MRP1, ABCG2 in vitro and in vivo. Its in vitro effect is related to the PI3K/AKT signaling pathway.

Identifiants

pubmed: 33167958
doi: 10.1186/s12906-020-03135-8
pii: 10.1186/s12906-020-03135-8
pmc: PMC7654161
doi:

Substances chimiques

Antineoplastic Agents 0
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

337

Subventions

Organisme : National Natural Science Foundation of China
ID : 81673918

Références

Medicine (Baltimore). 2019 Nov;98(47):e17875
pubmed: 31764782
Genet Mol Res. 2012 Sep 26;11(3):3497-504
pubmed: 23079843
Expert Opin Drug Saf. 2012 Nov;11(6):985-1002
pubmed: 22992190
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
BMC Cancer. 2011 Jul 29;11:322
pubmed: 21801359
Ann Oncol. 2014 Feb;25(2):544-5
pubmed: 24478324
Int J Clin Oncol. 2006 Feb;11(1):44-50
pubmed: 16508728
Cancer Chemother Pharmacol. 2010 Feb;65(3):579-87
pubmed: 19629485
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
J Exp Clin Cancer Res. 2016 Jan 04;35:1
pubmed: 26728266
Chin J Integr Med. 2016 Aug;22(8):581-8
pubmed: 27299458
J Neuroinflammation. 2019 May 8;16(1):95
pubmed: 31068207

Auteurs

Huijuan Tang (H)

Oncology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing, 210029, Jiangsu province, China.
Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, 60126, Ancona, Italy.

Wenjie Huang (W)

Oncology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing, 210029, Jiangsu province, China.

Qiang Yang (Q)

Oncology Department, Liyang Traditional Chinese Medicine Hospital, Liyang, 213300, China.

Ying Lin (Y)

Emergency Department, Suzhou Municipal Hospital of Integrative Medicine, Suzhou, 215000, China.

Yihui Chen (Y)

Gastroenterology Department, Jiangsu Jiangyin People's Hospital, Jiangyin, 214400, China.

Peng Shu (P)

Oncology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing, 210029, Jiangsu province, China. shupengsp@outlook.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH